Luc-andré Granier
M.D., PhD: CEO and Medical Director
Management
Advicenne
France
Biography
Luc-André Granier founded Advicenne and has been Medical Director and Chairman of the Board since 2011. Luc-André Granier is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system (CNS) with more than 25 years’ experience in the pharmaceutical (Eli Lilly and Co) and biotechnology (Synt:em, Forenap) industries. He has conducted a large number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, mainly in the fields of pain, migraine, neuro-degenerative diseases and psychiatric disorders. In particular, he successfully conducted the proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. Dr Granier obtained his degree as a Doctor of Medicine and Doctor of Science (in Biochemistry and Molecular and Cellular Biology) at the Louis Pasteur University in Strasbourg, France. He is a member of several national and international scientific societies, in particular in the fields of pain (SFETD, IHS, IASP) and epilepsy (ILAE).
Research Interest
Business Development
